17 FEBRUARY 2020
By David Tuller, DrPH
Last week,
I wrote to Rob Paull, the co-founder and CEO of Mahana Therapeutics, regarding the company’s misleading claims about the web-based cognitive behavior therapy program for irritable bowel syndrome it recently licensed from King’s College London. I have
also written to Professor Rona Moss-Morris, the co-lead investigator of ACTIB, the study that road-tested the program, as well as three of Mahana’s prominent gastroenterology advisors.
So far, no one has responded or attempted to explain why
Mahana is making unwarranted statements about the efficacy of the program. Presumably the company would like to have regulators in the UK and the US approve the product for public use. If so, it would be smart for Mahana and Mr Paull to be honest in describing what the findings do and do not show. So far, they have failed that test.
**********
Dear Mr Paull–
I have not heard back from the letter I sent last week about Mahana Therapeutics and the licensing deal for the Regul8 web-based cognitive behavior therapy program for people with irritable bowel syndrome. ...................
